Growth Metrics

Compass Therapeutics (CMPX) Free Cash Flow (2023 - 2026)

Compass Therapeutics' Free Cash Flow history spans 4 years, with the latest figure at -$17.4 million for Q1 2026.

  • On a quarterly basis, Free Cash Flow fell 31.19% to -$17.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$53.3 million, a 20.47% decrease, with the full-year FY2025 number at -$49.2 million, down 9.51% from a year prior.
  • Free Cash Flow hit -$17.4 million in Q1 2026 for Compass Therapeutics, down from -$13.3 million in the prior quarter.
  • Over the last five years, Free Cash Flow for CMPX hit a ceiling of -$5.9 million in Q3 2023 and a floor of -$17.4 million in Q1 2026.
  • Historically, Free Cash Flow has averaged -$11.7 million across 4 years, with a median of -$11.8 million in 2025.
  • The widest YoY moves for Free Cash Flow: up 25.89% in 2024, down 87.04% in 2024.
  • Tracing CMPX's Free Cash Flow over 4 years: stood at -$12.4 million in 2023, then grew by 25.89% to -$9.2 million in 2024, then tumbled by 44.66% to -$13.3 million in 2025, then crashed by 30.91% to -$17.4 million in 2026.
  • Business Quant data shows Free Cash Flow for CMPX at -$17.4 million in Q1 2026, -$13.3 million in Q4 2025, and -$10.9 million in Q3 2025.